Contact
searchSearch
HMP Global
Login

Test Deciphera 2021

Recent News

News
Real-World Study Demonstrates Clinical Activity of Lurbinectedin in Previously Treated Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz...
10/28/2026
Oncology
News
NETSARC+ Study Identifies Tumor Location and Size as Prognostic Factors in Patients With Desmoid Tumors
10/28/2026
Emily Estrada
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+...
10/28/2026
Oncology
News
G-CSF Prophylaxis Reduces Incidence of Febrile Neutropenia Without Compromising Chemoimmunotherapy Outcomes in Patients With Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter,...
10/28/2026
Oncology
News
Tambotatug Pelitecan Significantly Improves Overall Survival in Patients With Relapsed Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3...
10/28/2026
Oncology
News
Oral Hypomethylating Agents Show Comparable Hematologic Toxicity to Intravenous Therapy in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia
10/28/2026
Emily Estrada
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter...
10/28/2026
Oncology
News
Phase 3 Results Support Regulatory Submission of Oral Azacitidine Plus Cedazuridine in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
10/28/2026
Emily Estrada
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND...
10/28/2026
Oncology
News
Varegacestat Demonstrates Promising Antitumor Activity in Patients With Progressive Desmoid Tumors
10/28/2026
Emily Estrada
Results from the phase 2 RINGSIDE trial demonstrated sustained antitumor activity with varegacestat in patients with progressive desmoid tumors, with once daily dosing producing greater tumor volume reductions and higher response rates than...
Results from the phase 2 RINGSIDE trial demonstrated sustained antitumor activity with varegacestat in patients with progressive desmoid tumors, with once daily dosing producing greater tumor volume reductions and higher response rates than...
Results from the phase 2...
10/28/2026
Oncology
FDA Approval
FDA Expands Talazoparib Plus Enzalutamide Indication to HRR-Mutated Metastatic Prostate Cancer
10/26/2026
Emily Estrada
Based on results from the phase 3 TALAPRO-3 trial, the FDA has approved talazoparib plus enzalutamide for patients with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, following a significant...
Based on results from the phase 3 TALAPRO-3 trial, the FDA has approved talazoparib plus enzalutamide for patients with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, following a significant...
Based on results from the phase...
10/26/2026
Oncology
News
Reduced-Frequency Immunotherapy Fails to Demonstrate Noninferiority in Advanced Cancer in Phase 3 MOIO Trial
10/26/2026
Emily Estrada
Results from the phase 3 MOIO trial demonstrated that reduced-frequency immune checkpoint inhibitor treatment failed to establish progression-free survival noninferiority compared with standard dosing in patients with responding advanced or...
Results from the phase 3 MOIO trial demonstrated that reduced-frequency immune checkpoint inhibitor treatment failed to establish progression-free survival noninferiority compared with standard dosing in patients with responding advanced or...
Results from the phase 3 MOIO...
10/26/2026
Oncology
News
Risvutatug Rezetecan Reduces Progression Risk by 67% in Previously Treated Relapsed or Refractory Osteosarcoma
10/26/2026
Emily Estrada
Results from the phase 3 ARTEMIS-011 trial showed that risvutatug rezetecan significantly prolonged progression-free survival compared with gemcitabine plus docetaxel in heavily pretreated patients with relapsed or refractory osteosarcoma,...
Results from the phase 3 ARTEMIS-011 trial showed that risvutatug rezetecan significantly prolonged progression-free survival compared with gemcitabine plus docetaxel in heavily pretreated patients with relapsed or refractory osteosarcoma,...
Results from the phase 3...
10/26/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use